Arvinas and Pfizer Announce Positive Phase 3 Results for Breast Cancer Therapy

Arvinas, Inc. and Pfizer Inc. have reported positive topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant in patients with advanced ER+/HER2- breast cancer. The study demonstrated a statistically significant improvement in progression-free survival for patients with estrogen receptor 1-mutant (ESR1m) tumors compared to fulvestrant, surpassing its target hazard ratio. While the intent-to-treat population did not achieve statistical significance, vepdegestrant showed promise as a targeted therapy for patients with limited treatment options.

Vepdegestrant, an investigational oral PROTAC ER degrader, leverages the body’s natural protein disposal system to degrade the estrogen receptor. The drug, jointly developed by Arvinas and Pfizer, has received Fast Track designation from the FDA. While overall survival data remains immature, the trial will continue monitoring long-term outcomes. The companies plan to present detailed results at a medical conference later this year and engage with regulatory authorities for potential approval.